0.00Open0.00Pre Close0 Volume0 Open Interest5.00Strike Price0.00Turnover0.00%IV1198.70%PremiumAug 16, 2024Expiry Date0.00Intrinsic Value100Multiplier25DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma0.51Leverage Ratio--Theta--Rho--Eff Leverage--Vega
BioVie Stock Discussion
BIVI(.49) I think has bottomed at .42 - Good adds here at .40s for a run to $1. Has a large gap to $1.76 which is high target. Can use the .42 as a safety for stop loss
BIOR(.70) Filed for mixed shelf offering two weeks ago, been trying to find these…HC Wainwright has $15 Target on it, don’t believe it but I do like it for gap fill to 1.08 minimum. I think this is going to get ran up and offering dropped. Should get dips t...
NEWS
BioVie’s Bezisterim Demonstrates Potential Improvements in Sleep/Fatigue and Restless Leg Symptoms for Parkinson’s Disease Patients
BioVie announced promising results from a Phase 2a trial of their drug bezisterim for Parkinson's disease. Data presented at the XXIX World Congress on Parkinson's Disease and Related Disorders showed that patients treated with bezisterim in combination with levodopa/carbidopa experienced significant improvements in both motor and non-motor s...
NEWS
BioVie to Present Data Showing How NE3107 Potentially Restores Homeostasis via Specific Genes Associated with Dementia, Metabolism, and Inflammation Rhea-AI Impact (Low) Rhea-AI Sentiment (Neutral) Tags conferences Rhea-AI Summary BioVie Inc. (Nasdaq: BIVI) announced the approval of the non-proprietary name 'bezisterim' for NE3107, a potential treatment for neurological disorders. The company will present data at the 12th Annual Alzheimer's & Parkinson's Drug Development S...
The good news will be in “middle of summer 2024” or earlier , when partnership and BIV201 Phase 3 funding will be announced
No comment yet